Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of ustekinumab in pediatric Crohn's disease, ulcerative colitis, and juvenile psoriatic arthritis
ISRCTN36985527Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label trial of ustekinumab in Crohn's disease, autoimmune colitis and juvenile psoriatic arthritis (JPsA) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Adverse events, Clinical laboratory hematology and chemistry and 3 more. Started Aug 2021; status: active, not recruiting.
02
Drugs
ustekinumab
03
Conditions
Crohn's diseaseautoimmune colitisjuvenile psoriatic arthritis (JPsA)
Beyond the preview
Go deeper on ISRCTN36985527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN36985527.